Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080448 | 1.00 | CYP3A4 (0.49) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL2082379 | 0.89 | TDP1 (0.45) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL2082380 | 0.89 | TDP1 (0.45) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL9145398 | 0.89 | ADRB2 (0.47) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL9145403 | 0.89 | ADRB2 (0.47) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL116273 | 0.88 | ADRB2 (0.52) | TDP1ADRB2HTTKMT2AKDM4E | |
| SCHEMBL9096923 | 0.87 | STAT3 (0.48) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL21729419 | 0.87 | ADRB2 (0.46) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL9097649 | 0.87 | STAT3 (0.48) | CYP3A4TDP1ADRB2HTTKMT2A | |
| SCHEMBL9096926 | 0.87 | STAT3 (0.48) | CYP3A4TDP1ADRB2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021081267-A1 | QUINOLONE CARBOXYLIC DERIVATIVES | TAIGEN BIOTECHNOLOGY CO., LTD (TW) | 2021-04-29 | — | — | WO | disclosed |
| US-7915418-B2 | Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7902226-B2 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20100069435-A1 | METHOD OF SELECTIVELY INTRODUCING AMINO SUBSTITUENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7626029-B2 | Into a difluorobenzoic acid, for producting quinolonecarboxylic acid serving as synthetic antibacterial agent, medicament, agricultural chemical, or veterinary drug; ionic liquid solvents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-1336611-B1 | DEHALOGENO COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070123560-A1 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-05-31 | — | — | US | disclosed |
| US-20040063754-A1 | Dehalogeno compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1336611-A1 | DEHALOGENO COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063754-A1 | Dehalogeno compounds | DEK, PGLS, RPS27L | CYP3A4 198/4885TDP1 3606/4885ADRB2 3952/4885 |
| US-20100069435-A1 | METHOD OF SELECTIVELY INTRODUCING AMINO SUBSTITUENT | ASNS, DDC, NQO2 | CYP3A4 140/4885TDP1 4379/4885ADRB2 2654/4885 |
| US-20070123560-A1 | Dehalogeno-compounds | DEK, RPS27L, POLL | CYP3A4 277/4885TDP1 3358/4885ADRB2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.